immatics

Médias

Immatics and Roche Sign Cancer Vaccine and Immunotherapy Collaboration

Médias

Immatics Closes €34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer

Médias

Immatics Appoints Peter Chambré as Chairman

Médias

Immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA

Médias

Immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival